Rusan Pharma aims Rs 600-crore revenues in 2-3 years

Rusan Pharma, which specialises in pain management, opioid de-addiction & anti-infectives therapies, today said it aims to generate revenues of about Rs 600 crore over the next 2-3 years.

"We have clocked turnover of Rs 350 crore in FY17 and target to achieve Rs 600 crore in the next 2-3 years by expanding footprints in the overseas market," Rusan Healthcare Business Head Malavika Saxena told

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)